MedTrace Logo

LEO 27847 - A Study in Healthy Male Subjects

NCT01007383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-02-24

No results posted yet for this study

Summary

The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 27847 in healthy male subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 27847 will be administered to healthy male subjects. In Part 2, multiple doses of LEO 27847 will be administered to healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

LEO 27847

First in man

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Joseph Chiesa, MD · Covance

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007383 on ClinicalTrials.gov